Type 2 Diabetes Risk in Women With Gestational Diabetes
Ten to 50% of women with gestational diabetes (GDM), or glucose intolerance first recognized during pregnancy, develop diabetes within 5 years after delivery. Although intensive interventions can reduce diabetes incidence in women with impaired glucose tolerance, it is unknown if such strategies would be effective in women with GDM. Women with recent GDM, even though no longer pregnant, face significant barriers to lifestyle modification, including caregiving responsibilities and low perception of risk. Web-based programs can reinforce physical activity through visual feedback of pedometer output, tailored messaging, education, and on-line communities. Such a program is currently available for adults with chronic disease and is led by Dr. Richardson, a co-PI on this application. Using data from focus group and survey work conducted by Dr. Kim, the other co-PI, this program can be modified to women with recent GDM. For Specific Aim 1, we propose to adapt a chronic disease web-based pedometer program to women with recent GDM. For Specific Aim 2, we propose to conduct a pilot and feasibility study of the program. The intervention will last 12 weeks.
Status: Active, not recruiting (N/A). Started on July 1st, 2009.
Enrollment: 60 subjects
Study Type: Interventional
Study Design:
- Allocation: Randomized
- Endpoint Classification: Efficacy Study
- Intervention Model: Parallel Assignment
- Masking: Open Label
- Primary Purpose: Prevention
Conditions:
Interventions:
- Behavioral: Stepping Up to Health
Eligibility
Inclusion Criteria:
Gestational diabetes diagnosis within past three years
Access to computer with internet, USB port and Windows XP or Vista
Regular email user (weekly or more)
Can walk a block on her own
Sedentary (less than 150 minutes purposeful physical activity per week)
Exclusion Criteria:
Unable to consent legally
- Gender
Female
- Mininum Age
18 Years
- Maximum Age
N/A
- Healthy Volunteers
No
Resources
Source: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Authority: United States: Institutional Review Board
Locations
-
University of Michigan Health System
Ann Arbor
Michigan
48109
United States
Officials
Catherine Kim, MD, MPH (Principal Investigator, University of Michigan)
Sponsors
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (Lead Sponsor)
University of Michigan (Collaborator)
References
None.
Links
None.
- Date Verified
- September 1st, 2010
- First Received
- September 9th, 2010
- Last Changed
- September 9th, 2010
Information obtained from ClinicalTrials.gov on June 09, 2011. Link to the current ClinicalTrials.gov record.
All data in the Healia Clinical Trials Information Database and content displayed by the Healia Clinical Trials Search Engine are licensed from the National Institutes of Health (National Library of Medicine), which collects and maintains the data.
The Healia Clinical Trials Search Engine searches the data set at clinicaltrials.gov, providing up-to-date information about current clinical trials. In the Healia Clinical Trials Database you can find information on new experimental drugs, medical devices, and other types of treatments for all types of diseases. Each clinical trial description includes information about the phase of the trial (phase I, phase II, or phase III), the trial’s methods, such as whether it is a randomized, placebo controlled, double blind study, and the status of the trial including whether or not the trial is currently enrolling new participants.